Another biotech felt the chill of the bear market late Wednesday, engineering a round of layoffs in order to stay afloat through the end of next year. Microcap antibody player Atreca will lay off more than 25% of its workforce to extend its cash runway through 2023, the company announced Wednesday, giving it the money … Continue reading Bear market forces another biotech into layoffs, as antibody developer Atreca reduces headcount by more than 25%